Sign in
4/A

Changes in Ownership

Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-23-011781

Chief Financial Officer acquired 19,482 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
FRATES JAMES M Chief Financial Officer 2022-01-06 Conversion +19,482 19,482 I
Derivatives
FRATES JAMES M Chief Financial Officer 2022-01-06 Conversion · Series C-1 Preferred Stock −19,482 0 I
Loading xslF345X04/doc4a.xml…